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Abstract 
Diabetes mellitus is a metabolic disorder characterized by insufficient insulin secretion from 
pancreatic β-cells to maintain blood glucose homeostasis. The disease is triggered by autoimmune 
destruction of β-cells (Type 1) or by conditions reducing insulin sensitivity and negatively impacting 
on β-cell activities (Type 2). Without proper management, diabetic patients develop serious 
complications that reduce life quality and expectancy. Although a definitive cure is not on the 
horizon, biomarkers permitting early detection of the disease and identification of individuals at risk  
of developing complications would greatly improve diabetes care. MicroRNAs are small non-coding 
RNAs controlling gene expression and participating in many physiopathological processes. 
Hundreds of microRNAs are actively or passively released in the circulation and can be used to 
evaluate health status and disease progression. Both Type 1 and Type 2 diabetes are associated with 
distinct modifications in blood microRNA profile, sometimes detectable years before the 
manifestation of the disease. Moreover, circulating levels of certain microRNAs appear to be 
predictive of long-term complications. As discussed in this review, there are still technical and 
scientific obstacles to be overcome, but circulating microRNAs may soon become part of the 
diagnostic arsenal to identify individuals at risk for developing diabetes and its devastating 
complications.   
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Introduction  
Diabetes mellitus affects more than 350 million peoples worldwide and significantly contributes to 
morbidity and mortality in modern societies1. In industrialized countries, it is the leading cause of 
blindness, renal failure and nontraumatic lower limb amputations. Patients suffering from diabetes 
have also a higher risk of developing cardiovascular disorders and stroke rendering this disease a 
heavy socioeconomic burden2. Unfortunately, the prevalence of diabetes is increasing at a dramatic 
pace both in children and adults, as a result of modern lifestyle associated with reduced physical 
activity, overnutrition and obesity, but also as a consequence of population ageing. Indeed, 
according to estimates of the International Diabetes Federation, 552 million people are expected to 
be diabetic in 20301.  
Although the origin and etiologies of diabetes mellitus can be diverse, the disease is 
invariably characterized by deregulation of blood glucose homeostasis resulting from the incapacity 
of pancreatic β-cells to secrete appropriate amounts of insulin to sustain the demands of the 
organism. In this review, we will focus on Type 1 and Type 2 diabetes mellitus (T1DM and T2DM, 
respectively), the two principal forms of the disease. T1DM is an auto-immune disorder in which 
pancreatic β-cells are attacked and eliminated by the immune system. During the immune response, 
leucocytes infiltrating the pancreatic islets secrete pro-inflammatory cytokines that recruits cytotoxic 
T lymphocytes and contribute to β-cell dysfunction and death3. The immune reaction leads to 
progressive destruction of β-cells resulting in severe or complete insulin deficiency. T1DM 
generally develops during childhood or in young adults and accounts for 5-8% of all diabetes cases. 
T2DM includes the vast majority of the other cases. The pathogenesis of this disease is closely 
linked to genetic and environmental/life style factors, such as hypercaloric nutrition, lack of exercise 
and obesity. T2DM is initiated by loss of insulin sensitivity of target tissues, including liver, skeletal 
muscles and adipose tissues. This insulin resistant state can normally be compensated by expansion 
of the functional β-cell mass and by an increase in their insulin secretory activity. However, in 
genetically predisposed individuals, the β-cells are unable to sustain the increased insulin demand, 
leading to chronic hyperglycemia and to the onset of T2DM4.  
Despite intensive research, the causes of diabetes mellitus remain incompletely understood 
and a definitive cure is still not available. The therapeutic arsenal available today permits, if not to 
cure, at least to delay the progression of the disease. The efficacy of these treatments would be 
drastically improved by implementing them during the initial phases of the disease and by 
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identifying individuals with the highest probability of benefitting from the therapeutic intervention. 
This goal can only be achieved by identifying new biomarkers predicting and/or monitoring the 
progression of T1DM and T2DM and their long-term complications. The aim of this reviewis to 
summarize the weaknesses of available blood parameters and biomarkers currently used to detect 
T1DM and T2DM and to discuss the potential use of circulating miRNAs as a novel class of 
biomarkers. 
 
Classical biomarkers in diabetes 
According to the World Health Organization, the diagnosis of diabetes mellitus is based on 
measurements of blood glucose levels in the fasted state and following an oral glucose tolerance 
test5. A diabetic state is defined by glucose levels above 7.0 mmol/L (126 mg/dl) in the fastedstate 
and higher than 11.1 mmol/L (200 mg/dl) after an oral glucose tolerance test5. Other serum 
parameters such as glycated hemoglobin (HbA1c) or residual C-peptide can also be helpful to 
diagnose diabetes mellitus. 
 
Biomarkers for Type 1 diabetes mellitus 
T1DM is generally diagnosed when more than 80 to 90% of the pancreatic β-cells have been 
destroyed by the immune system6. The progression of the disease is slow (months to years) 
providing a potentially long period to identify and treat individuals at risk. Recent progress has been 
made to preserve the functions of residual β-cells at the onset of T1DM using immunosuppressive 
medications7, 8. At present, the efficacy of these treatments is limited, but significant improvements 
could probably be obtained if therapies were initiated at earlier stages of the disease when a larger 
number of β-cells is still present. Autoantibodies against islet antigens are often used as biomarkers 
for T1DM, since their presence in the blood is a hallmark of the disease. Several autoantibodies have 
been described, but those directed against islet cells (ICA), insulin (IAA), the tyrosine phosphatase 
IA-2 and IA-2β, glutamate decarboxylase (GADA) and the zinc transporter 8 (ZnT8) are the most 
reliable for recognizing individuals at risk for developing T1DM (see Table 1)6, 9. However, the use 
of islet autoantibodies as biomarkers faces important limitations: 1) autoantibodies appear relatively 
late in the course of T1DM, 2) although most individuals at the onset of T1DM are positive for at 
least some autoantibodies, many autoantibody-positive individuals will never develop the disease, 
and 3) autoantibodies are not suitable for monitoring therapeutic outcomes9. There is therefore a 
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need for additional biomarkers for T1DM to complement the information obtained from the presence 
of autoantibodies and other risk factors (age, family history, susceptibility genes, and environmental 
triggers).  
 
Biomarkers for Type 2 diabetes mellitus 
Individuals at risk to develop T2DM are currently identified by a combination of easily accessible 
serum parameters (including glucose, triacylglycerol, cholesterol, lipoproteins and HbA1c), physical 
characteristics (body mass index, waist-to-hip ratio, blood pressure and sex) and lifestyle habits 
(food consumption, physical inactivity and smoking). By combining all these traditional/classical 
biomarkers and risk factors, the probability of predicting the development of the disease ranges  
from 0.85 to 0.90 in a period of 5 to 10 years before the onset of T2DM10. Other molecules have 
emerged as potentially useful biomarkers (see Table 1), including hormones, cytokines, adipokines, 
ferritin and C-reactive protein11. None of these so-called novel biomarkers can individually predict 
T2DM manifestation efficiently but in combination they can achieve predictive values similar to 
those with classical biomarkers12.  
All these serum parameters efficiently predict the development of T2DM few years in 
advance in individuals already displaying metabolic alterations, but they are not specific for diabetes 
and are unable to assess disease susceptibility in the general population. Genotypic analysis could 
potentially complement the biomarkers for the identification of individuals susceptible to develop 
T2DM later inlife. However, so far the predictive values of genotypic traits has not exceeded 0.6011. 
Thus, there is currently a need for early and life-style-independent predictive factors enabling 
physicians to recognize persons at risk of developing T2DM.  
 
microRNAs 
MicroRNAs (miRNAs) are small non-coding RNA molecules of 21 to 23 nucleotidesthat function as 
translational repressors by partially pairing to the 3’untranslated (UTR) region of target messenger 
RNAs (see Box 1). These regulators of gene expression were first discovered in Caenorhabditis 
elegans13, 14 and later on in vertebrates and plants. According to recent estimates, the human genome 
encodes more than 1600 miRNA precursors, generating up to 2237 mature miRNAs 
(www.miRbase.org) each of whichhas the potential of controlling hundreds of targets. MiRNAs are 
now universally recognized as major regulators of gene expression and as key controllers of several 
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biological and pathological processes15. MiRNAs are produced from stem-loop precursor RNAs 
generated from independent transcriptional units or from introns of protein-coding genes (Box 1). 
These primary transcripts (pri-miRNAs) are initially processed to produce shorter RNA molecules 
(pre-miRNAs) and then exported to the cytosol where they are further cleaved to generate the mature 
forms of the miRNAs (Fig.1). The mature miRNAs can either be included in the RNA-induced 
silencing complex (RISC) to guide translational repression of target mRNAs or be released by the 
cells. In the latter case, the miRNAs associate to proteins, to lipoproteins or are loaded inside 
vesicles that are released in the extracellular space upon plasma membrane blebbing or after fusion 
of multivesicular bodies with the plasma membrane (Fig.1).  
 
Role of miRNAs in diabetes pathogenesisPancreatic β-cells and insulin target tissues express a well-
defined set of miRNAs. Most of them are not cell specific, but are widely distributed throughout the 
human tissues. A notable exception is represented by miR-375, a miRNA highly enriched in 
pancreatic islets that regulates the expression of genes involved in hormone secretion and in β-cell 
mass expansion in response to insulin resistance16, 17. The miRNA expression profile of β-cells and 
insulin target tissues is altered both in T1DM and T2DM most likely contributing to impaired 
function of these tissues under disease states 18-20. Indeed, the islets of pre-diabetic NOD mice, a 
model of T1DM, contain increased levels of several miRNAs including miR-21, -34a, -29 and -146a 
which have deleterious impacts on β-cell functions 21, 22. Most of these miRNAs and many others are 
altered also in the islets ob/ob and db/db mice, two models of obesity and T2DM23, 24. Interestingly, 
in these animals the expression of miR-29 and -34a is also increased in insulin target tissues, 
possibly contributing to insulin resistance25, 26. Other miRNAs dysregulated in insulin target tissues 
of ob/ob mice, dietary mouse models of obesity and diabetic GK rats include miR-143, miR-802 and 
two closely related miRNAs, miR-103 and -107 25-28. There is strong experimental evidence 
indicating a contribution of these miRNAs to the development of insulin resistance in these obesity 
models26-28. MiRNA changes related to diabetes have also been reported in human tissues. More than 
sixty differentially expressed miRNAs were detected in human skeletal muscle biopsies from T2D 
patients, including an up-regulation of miR-143 and down-regulation of two muscle-specific 
miRNAs, miR-206 and miR-133a29. Interestingly, the level of about 15% of these miRNAs was 
already modified in individuals with impaired glucose tolerance suggesting an involvement in the 
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early phases of the disease process. The expression of part of these miRNAs is controlled by insulin 
but this regulatory mechanism appears to be impaired in diabetic patients 30. 
In addition to the changes in insulin target tissues described above, diabetes results in 
significant modifications in miRNA expression in blood vessels, heart, retina and kidneys indicating 
an involvement of these non-coding RNAs also in long-term diabetes complications (for review see 
19, 31, 32). 
 
A functional role for circulating miRNAs? 
Beside the gene regulatory activities accomplished inside the cells producing them, several miRNAs 
are found in blood and other body fluids in association with proteins, microvesicles and/or 
lipoprotein complexes33-35 (Fig.2). The function of circulating miRNAs remains to be established, 
but in vitro studies indicate that miRNAs transported by exosomes (see Box 2) or high-density 
lipoprotein (HDL) can be transferred in active form to recipient cells35, 36. This raises the intriguing 
possibility of an involvement of miRNAs in a novel cell-to-cell communication mode. Circulating 
miRNAs are very stable and resistant to RNAse treatment, freezing/thawing cycles and other drastic 
experimental conditions37, 38. Consequently, serum or plasma samples can be stored at -20 °C or -80 
°C for up to several months without significant miRNA degradation39, suggesting that these small 
RNA molecules are sufficiently robust to serve as biomarkers. Circulating miRNAs present several 
other advantages as potential biomarkers: they are found not only in blood but also in other easily 
accessible biological fluids (like urine, saliva, amniotic fluid and maternal milk)40, they can be 
detected by highly sensitive and specific quantitative PCR methods, and most of them are 
evolutionary conserved, facilitating the translation of results obtained from in vivo animal studies to 
human healthcare. Moreover, miRNA serum profiles of healthy donors are relatively homogenous 
and constant during the day and miRNAs can be measured in both serum and plasma38, 41, 42.  
 
miRNAs as diabetes biomarkers 
The idea of using blood miRNAs as biomarkers is relatively new and was first proposed for 
detecting different forms of cancer38, 43, 44, autoimmune diseases45 and sepsis46.  Recent studies have 
also analyzed the miRNA profile in serum, plasma or blood cells in attempt to develop new 
approaches to predict diabetes development and progression (summarized in Table 2). Zampetaki 
and colleagues were the first to identify a characteristic blood miRNA expression profile related to 
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T2DM47. In their prospective study, they analyzed blood samples of more than 800 individuals from 
the Bruneck cohort and identified a subset of 5 miRNAs (miR-15a, -28-3p, -29b, -126 and -223, and 
miR-28-3p) that display a characteristic deregulation in 80 pre-diabetic and diabetic subjects. 
Importantly, the level of these miRNAs was already modified years before the onset of the disease, 
providing initial evidence for the usefulness of circulating miRNAs as early predictors of T2DM and 
its vascular complications. The miRNA serum content of pre-diabetic and/or newly diagnosed 
T2DM patients was analyzed also by other groups. Kong and co-workers detected an increase in the 
expression of seven diabetes-related miRNAs (miR-9, -29a, -30d, -34a, -124a, -146a and -375) in 
T2DM patients compared to pre-diabetic or T2DM susceptible subjects48. However, no differences 
were observed between normal glucose tolerant and pre-diabetic individuals indicating that the level 
of these miRNAs is not suitable to predict T2DM susceptibility. More recently, Karolina et al. 
measured the miRNAs present in the blood and in exosomes of 265 patients with different health 
conditions associated with metabolic syndrome49. They detected an up-regulation of miR-27a, -150, 
-192, -320a, and -375 in T2DM individuals and observed a strong correlation between elevated 
fasting glucose concentrations and the alteration of miR-27a and miR-320a levels. These pioneering 
studies demonstrate the potential of miRNAs as biomarkers for T2DM. However, the heterogeneity 
of the results obtained underscores the need for large prospective studies to identify reliable miRNA 
signatures for T2DM. 
A similar approach was attempted to identify new biomarkers predicting destruction or 
regeneration of residual β-cells in T1DM. Nielsen and colleagues compared two cohorts (Danish and 
Hvidoere) of newly diagnosed for T1DM to an age-matched control group 50. Global miRNA 
sequencing, followed by qPCR verification, and regression analysis to adjust for age, sex and 
multiple testing, highlighted a group of miRNAs (miR-24, -25, -26a, -27a, -27b, -29a, -30a-5p, -
148a, -152, -181a, -200a and -210) that were differentially expressed in diabetes cohorts compared 
to control groups. Several of these miRNAs modulate the expression of genes involved in apoptosis 
and/or important β-cell regulatory networks50. Moreover, miR-25 levels were found to correlate with 
residual β-cell function (C-peptide measurement) and adequate glycaemic control (HbA1c levels) 3 
months after disease onset (Danish cohort). This correlation was not observed in the Hvidoere 
cohort, in which glycaemic control was evaluated 12 months after the diagnosis of T1DM. In a study 
presented at the last meeting of the European Association for the Study of Diabetes, Sebastiani and 
co-workers compared the blood miRNA profile of 20 newly-diagnosed T1DM patients with that of 
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healthy individuals51. Out of 206 miRNAs detected in serum of both groups, 64 were found to be 
differently expressed in T1DM. Interestingly, some of these miRNAs regulate the functions of 
immune cells (miR-31, -146a -155, -181a, -199a) or of β-cells (miR-9, 34a). A miRNA abundantly 
expressed in the islets of Langerhans, miR-375, has been recently proposed as suitable biomarker to 
detect β-cell death and to predict the development of T1DM in animal models. Indeed, massive β-
cell loss elicited by administration of streptozocin caused a dramatic rise in circulating levels of this 
miRNA52. Moreover, plasma levels of miR-375 were significantly increased in NOD mice two 
weeks before the onset of T1DM52. The changes in miR-375 levels consequent to β-cell death were 
short-lived. Thus, these promising findings obtained in mice will need to be verified in humans in 
which the decline of the β-cell mass spans much longer periods. Instead of analyzing plasma 
samples, other studies focused their attention on blood cells and measured the expression of specific 
miRNAs thought to play important roles in the immune reaction. Salas-Pérez et al. observed 
diminished expression of miR-21a and miR-93 in peripheral blood mononuclear cells (PBMC) of 
T1DM patients compared to healthy controls53. The reduction of miR-21a (but not of miR-93) could 
be reproduced by incubating PBMC from control individuals in the presence of 25 mM glucose, 
suggesting that it may be the consequence of chronic hyperglycemia. Finally, Sebastiani and 
colleagues analyzed miRNA expression in blood lymphocytes from T1DM individuals and observed 
a rise in miR-326 levels that correlated with the islet autoimmune attack54. The primary goal of the 
latter two studies was to identify miRNAs potentially involved in the development of the disease. 
However, since a large fraction of serum miRNAs are released by blood cells, it is possible that the 
miRNA changes in PBMC and/or lymphocytes observed in these two studies may yield detectable 
differences in plasma levels permitting to monitor the autoimmune reaction. 
 
Prediction of diabetes complications 
Both T1DM and T2DM are associated with long-term micro- and macrovascular complications with 
a devastating impact on life quality and expectancy. The discovery of biomarkers capable of 
identifying individuals at risk for experiencing serious complications such as retinopathy, 
nephropathy or cardiovascular disorders would permit to tailor the therapeutic approaches and 
minimize the expected impact of the disease. However, reliable biomarkers for these long-term 
complications are still missing.  
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Cardiovascular complications constitute a main concern since they account for up to 80% of 
premature mortality in diabetic patients55. Prevention, or even a delay, of these complications would 
represent a major advancement in the treatment of diabetes. As discussed above, Zampetaki and 
colleagues identified a unique plasma miRNA signature in T2DM patients47. Among the miRNAs 
displaying characteristic changes, the level of miR-126 showed the strongest association with 
T2DM, and correlated with the occurrence of subclinical and overt artery diseases. Interestingly, 
another study also reported down-regulation of miR-126 in blood samples obtained from patients 
suffering from coronary artery disease56. This miRNA is highly enriched in endothelial cells where it 
plays important roles in cell homeostasis and vascular integrity57, 58. Moreover, the level of miR-126 
released in apoptotic bodies is reduced by chronic exposure of endothelial cells to elevated blood 
glucose levels47 making this miRNA an ideal candidate biomarker for monitoring diabetic vascular 
complications. Another endothelial cell miRNA that deserves further attention is miR-503. The level 
of this small non-coding RNA is up-regulated in muscle biopsies and in peripheral blood-derived 
plasma of diabetic patients with limb ischemia59. Interestingly, local inhibition of miR-503 in a 
murine model of limb ischemia was able to improve vascular healing and blood flow recovery59. 
Other circulating miRNAs have also been suggested as diagnostic markers for various 
cardiovascular diseases (reviewed recently in60, 61), but their use in predicting or monitoring 
cardiovascular complications in diabetic patients remains to be investigated.   
Kidney disease affects  20-30% of T1DM and T2DM patients. Microalbuminuria was 
previously proposed as a biomarker to predict the occurrence of this important complication, but 
recent studies revealed that a significant fraction of the diabetic patients undergo renal failure before, 
or even without, detectable microalbuminuria62-64. Circulating miRNAs represent a good alternative 
way of monitoring renal failure in diabetic patients. They are not eliminated by hemodialysis65 and 
have already been tested in different renal diseases with  promising results in both animal models 
and human patients66-68. Indeed, a correlation was observed between some specific circulating 
miRNAs and glomerular filtration rate, a well-known parameter of kidney disease progression66. 
Large scale prospective studies focusing on diabetic patients undergoing renal failure will be 
necessary to identify a specific miRNA profile in plasma or urine predicting the appearance of this 
complication. Urine represents an ideal source of miRNAs since it can be easily collected in a non-
invasive manner and in large amounts. Moreover, urinary exosomes originate from various cell types 
spanning over the entire urinary track and would be ideally suited to monitor the progression of renal 
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diseases69-72. Indeed, urinary miRNA profiles were recently reported to differ across the stages of 
diabetic nephropathy73, suggesting that they may be used as tools to follow the progressive alteration 
of the renal processes. 
To our knowledge, there is at present no published report about the use of circulating 
miRNAs to predict diabetic retinopathy. However, recent studies have demonstrated an involvement 
of some specific miRNAs in the development of this complication (reviewed in32). These findings 
may open the door to future investigations aimed at assessing the potential use of miRNAs as 
predictors of this debilitating condition. 
 
Gestational diabetes 
Circulating miRNAs could in principle also be used to identify women at higher risk of developing 
gestational diabetes. At present, most screening protocols are based on a glucose challenge test 
performed around the 24-28th gestational weeks. Therefore, interventions such as diet, exercise or 
medication, are sometimes started as late as the 32nd week of gestation. In a multistage retrospective 
study, Zhao and colleagues screened miRNAs in serum of women at 16-19 weeks of gestation and 
identified three miRNAs (miR-29a, -122 and -132) that were deregulated in women developing 
gestational diabetes prior to detectable changes in blood glucose levels74. Placental specific miRNAs 
can be detected in maternal serum41, 75. Thus, it is possible that gestational diabetes may lead to 
changes in blood miRNAs that differ from those of T1DM or T2DM.  
 
Future directions 
The findings described above confirm the attractiveness of miRNAs as novel biomarkers for 
diabetes. Indeed, changes in the levels of a subset of these small RNA molecules in body fluids 
promises to provide new clues for early identification of individuals at risk to develop diabetes and 
their associated complications, for following disease progression or for assessing the efficacy of 
therapeutic interventions. However, as discussed below, before these goals can be achieved major 
scientific and technical advances need to be made.  
Circulating miRNAs should substitute or complement other routine measurements. Thus, 
their efficacy in predicting the appearance of diabetes or its complications needs to be systematically 
compared to already available biomarkers. In particular, it will be essential to scrutinize whether 
miRNAs are indeed able to provide earlier and/or more precise detection of individuals at risk for 
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developing the disease or its long-term complications. The situation will hopefully evolve in the 
future, but for most published studies there is for the moment no obvious advantage of replacing 
other traditional biomarkers with measurements of circulating miRNAs levels.  
Different papers have reported miRNA changes associated with diabetes or its complications 
but, for various reasons, we are still very far from a consensus about the most relevant miRNAs to be 
measured. This can in part be attributed to the heterogeneity of the approaches selected by the 
investigators. Some of the published studies carried out systematic profiling of a large number of 
miRNAs47, 49, 50 while others focused on a small group of selected miRNAs that were supposedly 
more likely to be affected in diabetes48, 52-54. This yielded a large number of potentially interesting 
candidates but most of them still await confirmation by independent researchers and/or in larger 
cohorts. Standardized protocols for sample preparation, RNA extraction and miRNA analysis are 
urgently needed to facilitate comparison between different studies and to reach a consensus about the 
miRNAs most suitable to function as early diabetes biomarkers. In fact, the level of certain plasma 
miRNAs is greatly influenced by the degree of hemolysis and by cellular contamination, rendering 
them less suitable as clinical biomarkers76.  
Diabetes mellitus is a complex disorder involving major metabolic alterations and important 
adaptations in the activity of several organs. MiRNAs are proposed as potential biomarkers for an 
increasing number of disease states. Therefore, it will be essential to determine whether the detected 
miRNA changes are exclusively indicative of a prediabetic or diabetic condition or if they are 
observed also in other physiological or pathological situations42 such as in response to modifications 
in the nutritional state, inflammation, autoimmunity, cancer, etc. 
At present, the origin of blood miRNAs is largely unknown and their levels do not directly 
mirror changes in pancreatic β-cells or insulin target tissues occurring in diabetes. MiRNAs can be 
actively or passively released by a variety of cells and can be carried by membrane-bound vesicles, 
protein complexes or lipoprotein particles (Fig.1 and 2). So far, the vast majority of studies measured 
the level of the miRNAs directly in the plasma (or serum). This is obviously a convenient and 
straight forward approach. However, modifications in the level of miRNAs originating from specific 
groups of cells that are not in direct contact with the blood or are not very abundant are unlikely to 
have a significant impact on the pool of plasmatic miRNAs and will probably go undetected. 
Although technically demanding, protocols allowing a specific assessment of the miRNAs carried by 
exosomes, protein complexes or lipoproteins will probably furnish more detailed information about 
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the physiological or pathological status of the organs of interest. Furthermore, it may be possible to 
affinity-purify membrane-bound vesicles originating from a specific group of cells taking advantage 
of the presence of characteristic proteins on the vesicle surface11. This approach will be particularly 
appropriate to estimate the residual β-cell mass in newly diagnosed T1DM patients. Indeed, except 
in the case of a sudden loss of a significant number of β-cells, the miRNAs released by insulin-
secreting cells represent only a negligible fraction of all non-coding RNAs circulating in the blood. 
This problem may be partially overcome by searching for miRNAs highly enriched in β-cells such 
as miR-37516, 52. However, the expression of this particular miRNA is modified in a variety of 
tumoral cells and several authors have suggested using circulating levels of this non-coding RNA for 
the diagnosis of different types of cancer77-80. Several insulin-secreting cell lines release significant 
amounts of exosomes81-83 and we have initial evidence indicating that this is the case also for rodent 
and human islet cells84. Protocols permitting an enrichment of exosomes derived from islet cells 
would probably improve the detection of specific changes in insulin-secreting cells and provide a 
better evaluation of the functional β-cell mass. 
 
Conclusions 
MiRNAs are emerging as important regulators of gene expression and central players in many 
physiological and pathological processes. Their presence in extracellular fluids in astonishingly 
stable forms has led to the idea of using them as biomarkers for a variety of diseases. These 
properties have attracted also the attention of diabetologists who have initiated the search for 
miRNAs allowing early detection of T1DM and T2DM and their associated complications. There are 
certainly still a number of scientific and methodological issues to be addressed before circulating 
miRNAs can attain the status of diabetes biomarkers, but the available data suggest that they will 
soon serve as valuable new blood parameters that will help physicians to refine  their therapeutic 
interventions.   
Key points 
 
- There is a need for new biomarkers to improve the identification of individuals at risk of 
developing diabetes and its associated complications, to follow disease progression and/or to assess 
the efficacy of therapeutic interventions. 
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- Circulating miRNAs are very attractive biomarker candidates since they can easily be collected, are 
stable under different storage conditions and can be measured using assays that are specific, 
sensitive and reproducible. 
 
- Pioneer studies have identified characteristic changes in blood miRNA levels in samples of diabetic 
patients from different cohorts. However, definitive consensus signatures for T1DM, T2DM or their 
associated complications remain to be defined. 
 
- Although measurements of circulating miRNAs promise to improve the identification of 
individuals prone to develop diabetes and its complications, a number of key issues including the 
determination of the most appropriate blood sampling protocols (serum, plasma, exosomes, etc.) 
remain to be addressed. 
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Boxes  
Box 1 miRNA biogenesis 
miRNAs are generated from intergenic genomic sequences or by intronic regions of protein-coding 
genes. miRNA precursors belonging to the latter category are therefore co-transcribed with their 
hosting gene85. Most mammalian miRNAs are transcribed by RNA polymerase II as long precursor 
molecules containing a characteristic stem-loop structure86. These primary transcripts are cleaved by 
the RNase III-type enzyme Drosha to produce hairpin-structured pre-miRNAs of about 70 
nucleotides. These molecules are then transported via an Exportin-5-dependent process into the 
cytoplasm, where they are further cleaved by the endoribonuclease Dicer to generate imperfect 
miRNA/miRNA* duplexes of ~22 nucleotides. The guide miRNA strand of this duplex is 
incorporated together with Argonaute proteins into the RNA-induced silencing complex (RISC). The 
passenger miRNA* strand is usually degraded but can sometimes also be loaded into the RISC 
complex and be functional. The majority of the miRNAs are generated by this canonical pathway, 
but alternative pathways have recently been described87, 88. Mature miRNAs exert their action by 
guiding the RISC complex to complementary sequences within the 3’UTR of target mRNAs, leading 
to translational repression and/or transcript degradation89. Target recognition is mainly determined 
by miRNA complementarity with the so-called “seed sequences” (i.e. residues 2-8) of target 
mRNAs89, 90. Interestingly, a single miRNA can potentially bind and regulate the expression of 
hundreds of targets, whereas a single 3’UTR region can be targeted by numerous different 
miRNAs90.  
 
 
Box 2 Exosomes 
Exosomes are microvesicles of 30 to 120 nm that were first observed to be released by reticulocytes 
in 1980s91-93. Since then, exosomes have been detected in the culture media of most cell types and 
were abundantly found in several body fluids like blood, urine, saliva and breast milk40. Vlassov et 
al. have estimated the concentration of exosomes in the blood to be around 3 million per microliter94. 
These vesicles display a characteristic size, form and lipid bilayer structure that can be visualized by 
electron microscopy. Exosome markers, such as the tetraspanins CD63 and CD81 and the Escort 
proteins Alix and Tsg101, are also routinely used to distinguish exosomes from other vesicles 
secreted by cells. Detailed analysis of the exosome content revealed that they can carry proteins and 
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nucleic acids (mRNAs, miRNAs and long non-coding RNAs)36, 95. The interest in exosomes 
increased dramatically in the past 5 years, after the discovery that their cargo can be transferred in 
active form to recipient cells36, 96, 97, leading to the exciting concept of exosomes as messengers of a 
new cell-to-cell communication mode. However, the precise mechanisms leading to exosome release 
and/or uptake remain to be elucidated. Exosomes are produced inside cells via the multivesicular 
endosomal pathway92, 93 but very little is known on the selective packaging of nucleic acids and 
proteins composing the exosome cargo. A better understanding of these mechanisms may reveal new 
biological roles for exosomes in healthy state, but also in pathophysiological conditions. 
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Figure legend 
 
Fig.1 : Biogenesis and release of miRNAs 
MiRNA precursors (pre-miRNAs) are generated in the nucleus by the RNase III enzyme Drosha 
after cleavage of primary RNA transcripts (pri-miRNAs) (1). The pre-miRNAs are then transported 
in the cytoplasm through a process involving Exportin-5 and the GTP-binding protein Ran (2) and 
further cleaved by Dicer to yield 21-23 nucleotide duplexes (3). One strand of the miRNA duplex 
can either associate to the RISC complex and guide translational repression of target mRNAs (4) or 
be released by the cells. In the latter case, the mature miRNA binds to RNA-binding proteins such as 
Argonaute 2 (5) or to lipoproteins (6). Alternatively, the miRNAs can be loaded in microvesicles 
formed by plasma membrane blebbing (7) or in exosomes that are released in the extracellular space 
upon exocytic fusion of multivesicular bodies with the plasma membrane (8). 
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Fig.2: Blood and other body fluids contain active miRNAs 
MiRNAs can be released or shed by cells and are found in stable form in body fluids. The miRNAs 
present in the blood are associated with protein complexes including Argonaute 2, or with HDL 
particles, or are transported inside membrane-bound vesicles such as exosomes (1). There is 
evidence that circulating miRNAs can be taken up in active form through different mechanisms 
including receptor-mediated capture, endocytosis or fusion of exosomes with the plasma membrane 
of receiving cells (2). Transfer of miRNAs between distantly located cells constitutes a potentially 
new communication mode. 
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Tables  
 
Table 1 : Blood parameters and biomarkers currently used to predict and diagnose T1DM and T2DM 
Type of 
diabetes 
              Blood parameters/Biomarkers 
Type Name Symbol 
T1DM and 
T2DM Blood parameters Glycaemia  - 
  Glycated hemoglobin  HbA1c 
T1DM Autoantigens Glutamate decarboxylase GADA 
  Insulin IAA 
  Islet cells ICA 
  Tyrosine phosphatases IA-2, IA-2β 
  Zinc transporter 8 ZnT8 
T2DM    
    
    
    
    
    
 Traditional biomarkers Cholesterol - 
  Creatinine - 
  Free fatty acids FFA 
  α-hydroxybutyrate α-HB 
  Lipoproteins HDL 
  Triacylglycerol Tg 
    
 Novel biomarkers Adipokines - 
  C-reactive protein CRP 
  Cytokines - 
  Ferritin - 
  Incretins GLP-1 
  Linoleoylglycero- phosphocholine L-GPC 
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Table 2 : Blood miRNA changes associated with diabetes mellitus 
Study design Source Method of analysis miRNAs identified Observations Ref. 
T2DM 
     
800 ind. from  
Bruneck cohort Plasma 
microarray profiling 
(confirmed by qPCR) 
miR-15a, -28-3p, -29b, -
126 and -223 
First study to suggest a 
blood miRNA signature 
for T2DM 
47 
56 ind. with  
health conditions 
related to DM 
Serum qPCR on  specific miRNAs 
miR-9, -29a, -30d, -34a,  
-124a, -146a and -375 Deregulated in T2DM 
48 
265 ind. with health 
conditions related to 
metabolic syndrome 
Blood microarray profiling (confirmed by qPCR) 
miR-150, -192, -27a,  
-320a and -375 
Correlation between 
elevated FG and altered 
levels of miR-27a and -
320a 
49 
T1DM      
Danish and 
Hvidoere cohorts of 
newly diagnosed 
children 
Serum microarray profiling (confirmed by qPCR) 
miR-24, -25, -26a, -27a,  
-27b, -29a, -148a, -152,  
-181a, -200a and -210 
miR-25 negatively 
correlated with residual  
β-cell function 
50 
20 newly diagnosed 
T1DM patients Serum 
microarray profiling 
(confirmed by qPCR) 
miR-9, -31, -34a, -146a,  
-155, -181a and -199a 
Deregulated 
 in T1DM 
51 
20 patients with 
T1DM PBMC 
qPCR on  
specific miRNAs miR-21a and miR-93 
Underexpressed  
in T1DM 
53 
19 patients with 
T1DM 
Lympho- 
cytes 
qPCR on  
specific miRNAs miR-326 
Correlation with islet 
autoimmune attack 
54 
 
Abbreviations: Ref = references, ind.= individuals, DM = diabetes mellitus, T1DM = Type 1 
diabetes mellitus, T2DM = Type 2 diabetes mellitus, FG = fasting glucose and PBMC = peripheral 
blood mononuclear cells. 
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Review criteria 
 
We systematically searched Pubmed using different combinations of the following words: diabetes, 
type 1 diabetes, type 2 diabetes, gestational diabetes, diabetes complications, diabetic retinopathy, 
diabetic nephropathy, cardiovascular complications, biomarkers, microRNAs, circulating miRNAs 
and exosomes. We also scrutinized the appropriate references cited in the selected papers. Two 
abstracts from the EASD meeting 2012 held in Berlin were also included. Because of space 
limitations, not all original articles could be listed in the present review. Whenever possible, the 
most recent and complete reviews on the topic were chosen. All selected articles were in English. 
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